Everett Harris & Co. CA boosted its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 0.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 113,803 shares of the biopharmaceutical company’s stock after buying an additional 330 shares during the quarter. Everett Harris & Co. CA’s holdings in Pfizer were worth $4,643,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC raised its stake in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Norges Bank purchased a new position in shares of Pfizer during the fourth quarter worth approximately $3,150,472,000. Morgan Stanley raised its stake in shares of Pfizer by 10.3% during the fourth quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after acquiring an additional 7,419,929 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Pfizer by 13.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after acquiring an additional 6,972,650 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Pfizer during the first quarter worth approximately $311,238,000. Institutional investors own 67.80% of the company’s stock.
Analyst Ratings Changes
Several research firms have commented on PFE. Wells Fargo & Company decreased their price target on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a research note on Friday, March 17th. Morgan Stanley cut their target price on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating on the stock in a report on Monday, April 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Pfizer in a report on Wednesday, May 17th. Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $47.00 to $40.00 in a report on Thursday, June 29th. Finally, Barclays cut their target price on shares of Pfizer from $43.00 to $40.00 in a report on Wednesday, May 3rd. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $46.67.
Pfizer Stock Performance
Pfizer (NYSE:PFE – Free Report) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The firm had revenue of $18.28 billion for the quarter, compared to analysts’ expectations of $16.49 billion. During the same quarter in the previous year, the business posted $1.62 EPS. The company’s quarterly revenue was down 28.8% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 3.35 EPS for the current fiscal year.
Pfizer Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be paid a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, July 27th. This represents a $1.64 dividend on an annualized basis and a dividend yield of 4.62%. Pfizer’s dividend payout ratio is currently 32.28%.
Insider Buying and Selling at Pfizer
In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Monday, May 8th. The stock was acquired at an average cost of $38.58 per share, for a total transaction of $38,580.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $231,480. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.05% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Read More
- Five stocks we like better than Pfizer
- EV Mixed Signals: Sales Are Rising, But Inventory Slower To Move
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
